UB-313 Migraine Vaccine Description
UB-313 is a novel immunotherapeutic vaccine candidate targeting calcitonin gene-related peptide (CGRP) for the preventive treatment of migraine.
CGRP causes vasodilation and neurogenic inflammation and is known to play an important role in migraine pathophysiology.
UB-313 is designed to trigger the production of antibodies that inhibit CGRP in patients with chronic and episodic migraine to reduce migraine frequency and severity.
UB-313 has entered a Phase 1 clinical trial.
UB-313 Migraine Vaccine News
September 13, 2022 - Vaxxinity, Inc. (Nasdaq: VAXX) announced that the first subjects have been dosed in a Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin gene-related peptide (CGRP), for the preventive treatment of migraine.